Peter Curtin, M.D.

“This man helped save my life ... he's amazing!” - Patient
1985, American Board of Internal Medicine, Medical Oncology
1984, American Board of Internal Medicine, Hematology
1982, American Board of Internal Medicine
1979, M.D., S.U.N.Y-Upstate Medical College, Syracuse, NY
1975, A.B., English Literature, Harvard University, Cambridge, MA
1984-1987, Postdoctoral fellow, Y.W. Kan laboratory, Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA
1982-1985, Hematology-Oncology, Cancer Research Institute and Department of Medicine, University of California San Francisco, San Francisco, CA
1979-1982, Internal Medicine, North Carolina Memorial Hospital, Chapel Hill, NC
2020-present, Professor, Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2007-2020, Professor of Clinical Medicine, Clinical Director,
Blood & Marrow Transplantation Division, Department of Medicine, University of California San Diego, La Jolla, CA2002-2007, Director, MDS Center of Excellence, Oregon Health & Science University, Portland, OR
2000-2007, Associate Professor, Division of Hematology and Medical Oncology, Oregon Health & Science University, Department of Medicine, Portland, OR
1998-2000, Assistant Professor, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR
1997-1998, Associate Director, Research, Cancer Genomics, Director of Laser Capture Microscopy and Tumor Sample Bank, Chiron Corporation, Emeryville, CA
1996-1997, Associate Director, Clinical Development, Project Leader: Interleukin-2 in HIV Disease, Chiron Corporation, Emeryville, CA
1996-1998, Assistant Clinical Professor, Department of Medicine, University of California San Francisco, San Francisco, CA
1993-1996, Assistant Professor, Division of Hematology and Oncology, Department of Medicine and Program in Genetics, Tufts University School of Medicine, Boston, MA
1989-1993, Acting Chief, Division of Molecular Hematology and Genetics, Department of Medicine, University of California San Francisco, San Francisco, CA
1989-1993, Assistant Professor, Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA
1987-1989, Clinical Instructor, Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA
2013, 2015, Hematology and Oncology, San Diego Magazine “Best Doctor”
1987, Lita Annenberg Hazen Fellow
1979, Alpha Omega Alpha, S.U.N.Y., Upstate Medical College
1975, A.B. cum laude in English literature, Harvard University
1998-2007, Member, Oregon Cancer Center, Oregon Health & Science University, Portland, OR
1998-2007, Member, Northwest Marrow Transplant Program, Oregon Health & Science University, Portland, OR
- Nguyen JC, Kubik MJ, Broome HE, Curtin PT, Dell'Aquila ML, Wang HY. Successful treatment of both double minute of C-MYC and BCL-2 rearrangement containing large B-cell lymphoma with subsequent unfortunate development of therapy-related acute myeloid leukemia with t(3;3)(q26.2;q21). Pathol Res Pract. 2015 Jul 17. pii: S0344-0338(15)00146-6. DOI: 10.1016/j.prp.2015.07.004. [Epub ahead of print] PMID: 26300063.
- Brammer JE, Stentz A, Gajewski J, Curtin P, Hayes-Lattin B, Kovacsovics T, Leis JF, Meyers G, Nemecek E, Subbiah N, Frires R, Palmbach G, Avraham GP, Slater S, Maziarz RT. Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population. Biol Blood Marrow Transplant. 2015 Jan;21(1):89-96. doi: 10.1016/j.bbmt.2014.09.024. Epub 2014 Oct 16.PMID: 25445641.
- Wong-Sefdan I, Ale-Ali A, DeMoor PA, Martinez S, Curtin P, Lane T, Roeland E. Implementing inpatient, evidence-based, antihistamine-transfusion premedication guidelines at a single academic US hospital.. J Community Support Oncol. 2014 Feb;12(2):56-64. PMID: 24971406.
- Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani BN, Scriber JR, Shaughnessy PJ, Wall DA, Carpenter PA. First and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012 Apr 14. [Epub ahead of print] PMID: 22510384.
- Wang HY, Thorson JA, Broome HE, Rashidi HH, Curtin PT, Dell’Aquila ML. t(4:22)(q12:q11.2) involving presumptive platelet-derived growth factor receptor A and break cluster region in a patient with mixed phenotype acute leukemia. Hum Pathiol. 2011 Dec;42(12:2029-36. Epub 2011 June 14. PMID: 216767437.
- Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, Williams S, Burris H 3rd, Faderl S, Estrov Z, Curtin P, Larson RA, Keck JG, Jones M, Meng L, Brown GL. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol. 2009 May 13;2:20.
- Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.Blood. 2008 Jan 1;111(1):86-93. Epub 2007 Sep 24.
- Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, Maris MB, Agura ED, Chauncey TR, Wong RM, Forman SJ, Petersen FB, Wade JC, Epner E, Bruno B, Bethge WA, Curtin PT, Maloney DG, Blume KG, Storb RF. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant. 2008 Feb;14(2):246-55.
- List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R. Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006 Oct 5;355(14):1456-65. Journal of Medicine.
- DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006 Dec 1;108(12):3674-81. Epub 2006 Aug 10.